Edition:
United States

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

3.60USD
11:06am EST
Change (% chg)

$0.20 (+5.88%)
Prev Close
$3.40
Open
$3.48
Day's High
$3.61
Day's Low
$3.44
Volume
19,899
Avg. Vol
68,441
52-wk High
$12.38
52-wk Low
$1.86

Chart for

About

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including... (more)

Overall

Beta: 0.18
Market Cap(Mil.): $146.31
Shares Outstanding(Mil.): 43.03
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 26.79 16.04
EPS (TTM): -- -- --
ROI: -- 8.22 34.69
ROE: -- 10.67 15.46

BRIEF-DSM acquires Brazilian production facility from Amyris

* DSM expands strategic alliance with Amyris and acquires Brazilian production facility from Amyris

Nov 17 2017

BRIEF-Amyris posts Q3 GAAP loss of $1.14 per share

* Amyris reports another strong quarter of product sales growth and expects strong finish for 2017

Nov 14 2017

BRIEF-Amyris files for offering of up to 26.2 mln shares of common stock by selling stockholders‍​

* Amyris Inc files for offering of up to 26.2 million shares of common stock by the selling stockholders - SEC filing ‍​ Source text: (http://bit.ly/2zaU4Od) Further company coverage:

Nov 03 2017

BRIEF-Amyris Inc enters into agreement with Koninklijke DSM N.V.

* Amyris enters into product development and production agreement with Royal DSM for human nutrition ingredient

Oct 05 2017

BRIEF-Amyris enters into second major product development with Royal DSM

* Amyris Inc enters into second major product development and production agreement with Royal DSM

Sep 26 2017

BRIEF-Amyris Q2 loss per share $0.46

* Amyris delivers another strong quarter with revenue of $25.7 million and product sales increase of 159% over 2nd quarter of 2016

Aug 10 2017

BRIEF-Vivo Capital VIII reports 9.9 pct stake in Amyris

* Vivo Capital VIII LLC reports 9.9 percent passive stake in Amyris Inc as of August 2, 2017 - SEC filing Source text: (http://bit.ly/2vCkff7) Further company coverage:

Aug 08 2017

BRIEF-Amyris files for offer and sale of up to 42.27 mln shares

* Amyris Inc files for offer and sale of up to 42.27 million shares of co's common stock by the selling stockholders - sec filing‍​ Source text: (http://bit.ly/2hwaLw0) Further company coverage:

Aug 04 2017

BRIEF-Amyris says second tranche of $50 mln in a private placement days is being led by a $25-mln investment from Koninklijke​

* Amyris announces agreements for $50 million in second tranche of equity financing, exceeding previous target of $95 million

Aug 03 2017

BRIEF-Amyris enters into first product development, production agreement with Royal DSM

* Amyris enters into first product development and production agreement with Royal DSM for food and nutrition molecule

Jul 17 2017

Earnings vs. Estimates